2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
|
|
- Francis Curtis
- 8 years ago
- Views:
Transcription
1 ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs), aka direct oral anticoagulants (DOACs) Identify patients who are appropriate for TSOACs Describe the reversal of TSOACs in case of bleeding or the need for surgery Discuss current, relevant research in TSOACS, including reversal agents BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS Vitamin K antagonists (VKA) inhibits the synthesis of vitamin K-dependent clotting factors: factors II, VII, IX, and X, and the proteins C and S Warfarin (Coumadin ) Direct Thrombin Inhibitors By inhibiting thrombin, prevents the conversion of fibrinogen to fibrin, thus preventing thrombus formation Dabigatran (Pradaxa ) Factor Xa inhibitors Prevents formation of thrombin, thus preventing the conversion of fibrinogen to fibrin and thrombus formation Apixaban (Eliquis ) Rivaroxaban (Xarelto ) Edoxaban (Savaysa ) 1
2 INDICATIONS FOR TSOACS: DABIGATRAN Dabigatran Atrial fibrillation: Approved for stroke prevention in people with nonvalvular atrial fibrillation Venous thromboembolism (VTE): Approved for the treatment of VTE, including pulmonary embolism (PE) and deep vein thrombosis (DVT) Approved for prophylaxis of VTE in people with a history of VTE Considerations: Twice daily dosing Cannot start immediately upon diagnosing VTE; must use parenteral anticoagulation for 5-10 days 80% renally cleared No antidote INDICATIONS FOR TSOACS: APIXABAN Apixiban Atrial fibrillation: Approved for stroke prevention in people with nonvalvular atrial fibrillation VTE prophylaxis: Approved for VTE prevention in people following hip or knee replacement surgery Considerations: Can start immediately following diagnosis of VTE Twice daily dosing 25% renally cleared No antidote INDICATIONS FOR TSOACS: RIVAROXABAN Rivaroxaban: Atrial fibrillation: Approved for stroke prevention in people with nonvalvular atrial fibrillation VTE: Approved for treatment and secondary prevention of VTE Approved for prevention of VTE in people with hip and knee replacement Considerations: Can start immediately following diagnosis of VTE Once daily dosing 33% renally cleared No antidote 2
3 NEWLY APPROVED TSOAC: EDOXABAN Edoxaban: Atrial Fibrillation: Approved for stroke prevention in people with nonvalvular atrial fibrillation VTE: Approved for the treatment of DVT and PE in people with an active clot Considerations: CANNOT be started immediately on diagnosis of VTE; must be treated for 5-10 days with parenteral antithrombotic Once daily dosing 35% renally cleared No antidote EDOXABAN AND ATRIAL FIBRILLATION: ENGAGE AF-TIMI 48 TRIAL RCT, double-blinded study of 21,105 participants Randomized either to warfarin at INR goal 2-3, high dose (60 mg), or low dose (30 mg) Median follow up 2.8 years Inclusion: 21 years or older, diagnosis of AF, CHADS 2 score >2 Exclusion: reversible cause of AF, CrCl < 30ml/min, high bleeding risk, dual anti-platelet therapy, mod-severe mitral stenosis, other indications for anticoagulation, ACS, coronary revascularization, stroke within 30 days of randomization, or inability to adhere to study protocol Purpose: compare to warfarin in terms of prevention of stroke or systemic embolization Note: TTR of warfarin was 68.4% EDOXABAN AND ATRIAL FIBRILLATION: PRIMARY OUTCOMES Group Event Analysis Warfarin High dose Low dose 1.5% per year 1.18% per year Hazard ratio 0.79 P<0.001 for inferiority; P=0.02 for superiority 1.61% per year Hazard ratio 1.07 P=0.005 for inferiority; P=0.44 for superiority 3
4 EDOXABAN AND ATRIAL FIBRILLATION: SAFETY Group Total Bleeding Events/Life- Threatening Bleeding Warfarin 3.43%/0.78% High dose Low dose Analysis 2.75%/0.40% Hazard ratio 0.80 P< %/0.25% Hazard ratio 0.47 P<0.001 EDOXABAN AND ATRIAL FIBRILLATION: CONCLUSIONS Edoxaban had lower rates of all bleeding compared to warfarin except GI bleeding (high-dose group) Anticoagulation-naïve patients had lower rates of stroke or embolism in the groups compared to the warfarin group Concomitant use of aspirin and amiodarone increased the efficacy of low-dose Dose reduction for kidney impairment and low body weight lowered bleeding risk in compared to warfarin High-dose is safer than and superior to warfarin for the prevention of stroke and systemic embolism in patients with AF EDOXABAN AND VENOUS THROMB0EMBOLISM RCT, double-blinded study of 4921 participants with DVT and 3319 with PE Randomized either to warfarin at INR goal 2-3, or 60 mg after initial treatment with heparin; participants with low body weight (<60kg),CrCl ml/min, or receiving P-glycoprotein inhibitors received 30 mg Received therapy 3-12 months Inclusion: 18 years or older, DVT or PE (diagnosed with imaging) Exclusion: contraindications to anticoagulation, receiving heparin for more than 48 hours, receiving more than 1 dose of warfarin, cancer, other indications for anticoagulation, receiving aspirin more than 100 mg daily, dual antiplatelet therapy, CrCl <30 ml/min Purpose: compare to warfarin in terms of recurrence of VTE Note: TTR of warfarin was 63.5% 4
5 EDOXABAN AND VTE: PRIMARY OUTCOMES Group Recurrence Analysis Warfarin 3.5% overall 6.2% in participants with PE and with RV dysfunction Edoxaban 60mg 3.2% overall 3.3% in participants with PE and with RV dysfunction Participants who Wafarin: 4.2% qualified for lowdose Edoxaban: 3.0% Hazard ratio: 0.89 P<0.001 for noninferiority Hazard ratio: 0.73 EDOXABAN AND VTE: SAFETY Group Total Bleeding Events/Major Bleeding Warfarin 10.3%/1.6% High dose Participants who Warfarin: qualified for lowdose 12.8%/3.1% Edoxaban: 7.9%/1.5% Analysis 8.5%/1/4% Hazard ratio 0.81 P=0.004 for superiority Hazard ratio 0.62 EDOXABAN AND VTE: CONCLUSIONS Edoxaban once daily, following initial parenteral treatment, is noninferior to warfarin at preventing recurrence of VTE and superior to warfarin in terms of bleeding Participants were followed for 12 months, regardless of treatment period; benefits were noted at 12 months even in those who stopped treatment after 3 months per CPGs Treatment included a lead in of heparin, followed by to recruit more severe VTEs; however, this is a possible limitation to the practical use of 5
6 WHAT DOES NONVALVULAR MEAN? RE-LY trial: No history of valve disorder, i.e., prosthetic valve or hemodynamically relevant valve disease Rocket AF trial: Hemodynamically significant mitral valve stenosis or a prosthetic heart valve; people with valve repair were included Aristotle trial: moderate to severe mitral stenosis, or situations other than atrial fibrillation that required anticoagulation, like a prosthetic heart valve No real consensus on the definition, so it is probably wise to avoid TSOACs in those with significant valve stenosis, prosthetic valves, or a history of rheumatic heart disease NEW DATA ON TSOACS SUBPOPUL ATIONS AND C O STS SAV INGS COSTS OF TSOACS COMPARED TO WARFARIN Drug Approximate Monthly Costs Warfarin $4-$19 Dabigatran $300 Apixaban $300 Rivaroxaban $400 Edoxaban? 6
7 COSTS IN OTHER TERMS Analysis of Medco data of plan participants with a diagnosis of AF from Jan Jun ,525 participants without valvular heart disease with a CHADS 2 score >1 Measured occurrence of stroke and other major bleeding in real world patients on warfarin Compared results to bleeding rates in warfarin arms major TSOAC trials: ARISTOTLE, RE-LY, ROCKET-AF COSTS, CONTINUED Results: Stroke and other bleeds were higher in Medco patients compared to participants randomized to warfarin arms of major TSOAC trials Stroke: 3 times higher in Medco patients on warfarin than outcomes in ARISTOTLE and RE-LY and 2 times higher than in ROCKET-AF Other major bleeds: over 3 times higher in Medco patients on warfarin than outcomes in ARISTOTLE, RE-LY, and ROCKET-AF Costs savings related to stroke were higher in those with a high baseline risk: CHADS 2 >3 and older adults FINDINGS AND INTERPRETATION Drug Number of strokes avoided per 100 patient years Number of major bleeds avoided per 100 patient years Cost difference Stroke/major bleeding Apixaban $493/-$752 Rivaroxaban* additional bleeds Dabigatran additional bleeds -$358/+$502 -$806/+$251 * Rivaroxaban is the only TSOAC with additional net costs 7
8 TSOACS IN OLDER ADULTS Meta-analysis of RCTs comparing TSOACs (rivaroxaban, apixaban, and dabigatran) to conventional therapy in participants >75 years old Conventional therapies: warfarin, low-molecular weight heparin (LMWH), aspirin, placebo 10 trials including 25,031 older adult participants with either AF or VTE Outcomes: Safety: major or clinically relevant bleeding Efficacy: VTE, VTE-related death, stroke, systemic embolism TSOACS IN OLDER ADULTS: BLEEDING Bleeding compared to conventional Stroke/ systemic Embolism compared to conventional VTE or VTErelated death All TSOACs Rivaroxaban Apixaban Dabigatran 6.4% vs 6.3% OR % vs 4.7% OR % vs 7.0% OR % vs 4.5% OR 1.18 Noninferior, OR 0.80 Noninferior OR % vs 7.3% OR 0.80 Noninferior OR 0.49 Noninferior OR % vs 8.7% OR 1.07 Noninferior OR 0.75 Unable to estimate from RCTs TSOACS IN OLDER ADULTS: CONCLUSIONS TSOACs did not cause more bleeding than conventional agents More effective than conventional therapies in preventing stroke or systemic embolism in older adults with AF compared to conventional therapies More effective than conventional therapies in preventing VTE or VTE-related death in older adults compared to conventional therapies Bleeding risk in older adults likely attributable to comorbidities (kidney disease) rather than age 8
9 TSOACS AND CANCER VTEs are common in patients with cancer Current guidelines by the American Society of Clinical Oncology Initial treatment with LMWH, fondaparinux, or unfractionated heparin (UFH) After 3 months (6-12 months indefinitely in people with active cancer, inherited thrombophilia, or patients receiving chemotherapy), LMWH is preferred over VKA VKA when LMWH is not possible TSOACS Sparse data on cancer patients Ongoing trial of apixaban for prevention of VTE in patients with cancer is promising, but no data on treatment in this cohort BENEFITS OF TSOACS Rapid onset and offset, assuming normal renal function Quick onset means requiring less parenteral anticoagulation in acute settings or for prophylaxis in high-risk settings Quick offset means less need for reversal in cases of planned surgery or less severe bleeding Predictable, so no routine monitoring or dose adjustment is required LIMITATIONS OF TSOACS No reversal agents Reversal may be required in settings of emergency surgery or severe bleeding (ICH) Missed doses mean negligible anticoagulation Less clear measures of anticoagulation activity compared to warfarin Kidney function is a major consideration Renal clearance means half-life can be prolonged, especially in dabigatran 9
10 MEASURING EFFECT OF ANTICOAGULATION WITH TSOACS PT/INR cannot assess level of anticoagulation in TSOACs PT (but not INR) may assess anticoagulant effect of rivaroxaban, but not apixaban Anti-Xa assays can be used for factor Xa inhibitors, using a chromogenic substrate, but are not yet useful clinically Diluted thrombin time for DTIs is available in Europe (HEMOCLOT) aptt can be used to measure effect of dabigatran, but the relationship changes over the action of the dose Peak concentration, aptt is 2-3 times control values Trough concentrations (about 12 hours after the last dose), aptt is 1.3 times control values WHAT DO WE DO WHEN THERE IS BLEEDING? Determine the severity of the bleeding! Consider the timing of the last dose! Assess kidney function to understand clearance! MILD-MODERATE BLEEDING Mild Bleeding Examples: epistaxis, gum bleeds Approach: hold the next few doses of the TSOAC Moderate Bleeding Examples: GI bleeding Approach: Hold the TSOAC Circulatory support with fluids and transfusion if necessary Identify source, and treat appropriately 10
11 REVERSING ANTICOAGULATION May be necessary in the case of severe bleeding or unexpected invasive procedures Consider timing of the last dose Methods: Withdraw agent Administration of reversal agent (antidote) Administration of specific clotting factors REVERSING TSOACS Activated charcoal If ingestion <6 hours ago (studied in apixaban in health volunteers) Emergent dialysis Dabigatran, in overdose or renal failure Prothrombin complex concentrates 3 and 4 factor varieties reversed in healthy volunteers on rivaroxaban; 4 factors varieties reduce PT more effectively Expensive and not widely available REVERAL AGENTS APPROVED Dabigatran Rivaroxaban Apixaban Activated PCCs (apcc) Platelet concentrates in those with thrombocytopenia or long-acting antiplatelets Dialysis PCCs may reduce PT Activated charcoal 2-6 hours after ingestion of last dose 11
12 REVERSAL MECHANISMS UNDER INVESTIGATION Dabigatran Apixaban Rivaroxaban Parenteral monoclonal antibody that binds to and reverses drug within 5 minutes of infusions Andexanet alfa binds to factor Xa inhibitors Binding of drug, resulting in reversal HOLDING PRIOR TO PROCEDURES Apixaban Dabigatran Rivaroxaban Procedures with moderate to high risk of bleeding: discontinue at least 48 hours prior Procedure with low risk of bleeding: discontinue at least 24 hours prior Discontinue 1-2 days (CrCl 50 ml/min) or 3-5 days (CrCl <50 ml/min) before invasive or surgical procedures Consider longer times for major surgery, spinal puncture, or spinal or epidural catheter or port Discontinue at least 24 hours prior to procedure REFERENCES Amin, A., Stokes, M., Makenbaeva, D., Wiederkehr, D., Wu, N., & Lawrence, J. H. (2014). Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. Journal of Medical Economics, 17, Elyamany, G., Alzahrani, A. M., & Bukhary, E. (2014). Cancer-associated thrombosis: an overview. Clinical Medicine Insights: Oncology, 8, Giugliano, R. P., et al, for the ENGAGE AF-TIMI 48 Investigators. (2013). Edoxaban versus warfarin in patients with atrial fibrillation. NEJM, 369, The Hokusai-VTE Investigators. (2013). Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. NEJM, 369,
13 REFERENCES Kasmeridis, C., Apostolakis, S., Ehlers, L., Rasmussen, L. H., Boriani, G., & Lip, G. Y. H. (2013). Cost effectiveness of treatments for stroke prevention I atrial fibrillation: focus on novel oral anticoagulants. PharmacoEconomics, 31, Levy, J. H., Spyropoulos, A. C., Samama, C. M., & Douketis, J. (2014). Direct oral anticoagulants: new drugs and new concepts. JACC: Cardiovascular Interventions, 7, Peacock, W. F. (2014). Managing bleeding and emergency revesral of newer oral anticoagulants: a review for primary care providers. Hospital Practice, 42, Sardar, P., Chatterjee, S., Chaudhari, S., & Lip, G. Y. H. (2014). New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. JAGS, 62,
The Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationNew Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationDOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant
DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X
More information48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.
48 th Annual Meeting Terminology Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding Stacy A. Voils, PharmD, MS, BCPS Navigating the Oceans of Opportunity Target-specific oral anticoagulants
More informationHow To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationComparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More information5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More informationVenous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationPost-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師
Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師 The antithrombotic efficacy is limited but the risk of bleeding is indefinite Fuster V et al. Circulation 2011;123:e269-e367
More informationManagement for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
More informationWarfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationTSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationBreadth of indications matters One drug for multiple indications
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationThe Brave New (Anticoagulant) World
The Brave New (Anticoagulant) World Diane M. Birnbaumer, M.D., FACEP Emeritus Professor of Medicine University of California, Los Angeles Senior Clinical Educator Department of Emergency Medicine Harbor-UCLA
More informationCOMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
More informationThrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:
More informationAnticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationDABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN
TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)
More informationDisclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationNHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS
NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016
More informationPrescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More informationRivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
More information3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationAnticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More informationSTARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis
More informationXabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
More informationSession 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
More information} Most common arrhythmia. } Incidence increases with age. } Anticoagulants approved for AF
Deniz Yavas, PharmD PGY-2 Ambulatory Care Pharmacy Resident Detroit Veterans Affairs Medical Center } Most common arrhythmia 0.4-1% of Americans (2.2 mil people) 1,2 } Incidence increases with age 6% (65
More informationThe New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012. Jeff Healey
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey RELY: A New Era in AF Connolly SJ et al. N Engl J Med 2009;361:1139-1151 ROCKET-AF:
More information1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
More informationStop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery
Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients
More informationNovel Anticoagulants
Novel Anticoagulants Kathleen Ozsvath, MD Associate Professor of Surgery, Albany Medical Center Partner, The Vascular Group, Albany, NY Chief of Vascular Services, Samaritan and St. Mary s Hospital, Troy,
More informationOptimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015
Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen
More informationDisclosures. I have served as an advisory board member, consultant, speaker, and / or received research funding from: Sanofi-Aventis
TSOACs: Glee Lenoir, Pharm D. Pharmacy Clinical Coordinator The Medical Center Nursing Conference March 2015 Disclosures I have served as an advisory board member, consultant, speaker, and / or received
More informationUpdates to the Alberta Human Services Drug Benefit Supplement
Updates to the Alberta Human Services Drug Benefit Supplement Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone
More informationThe Anticoagulated Patient A Hematologist s Perspective
The Anticoagulated Patient A Hematologist s Perspective Deborah M. Siegal MD MSc FRCPC Clinical Scholar Division of Hematology and Thromboembolism Thrombosis Canada Research Fellow McMaster University
More informationABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
More informationNon- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose. Warfarin vs the NOACs
Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose Warfarin vs the NOACs Dr. Lori McIntosh D.O. Board Certified Neurologist Objectives Be able to list the current options of
More informationAnticoagulation Essentials! Parenteral and Oral!
Anticoagulation Essentials! Parenteral and Oral! Anti-Xa and Anti-IIa! Parenteral Anticoagulants! Heparin family (indirect anti-xa and anti-iia):! UFH! LMWH (enoxaparin, fondaparinux)! Direct thrombin
More informationAnticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
More informationMCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment
More informationClinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications
Drugs (2014) 74:1587 1603 DOI 10.1007/s40265-014-0278-5 REVIEW ARTICLE Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications Toby Trujillo
More informationAre there sufficient indications for switching to new anticoagulant agents
Are there sufficient indications for switching to new anticoagulant agents Meyer Michel Samama et Gregoris Gerotziafas Groupe Hémostase-Thrombose Hôtel-Dieu, Hôpital Tenon, Paris & Biomnis Ivry/seine,
More informationDabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78
More informationTA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation 1 Name of Commissioning
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationAnticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
More informationDISCLOSURES CONFLICT CATEGORY. No conflict of interest to disclose
DISCLOSURES CATEGORY Employment Research support Scientific advisory board Consultancy Speakers bureau Major stockholder Patents Honoraria Travel support Other CONFLICT No conflict of interest to disclose
More informationUpdates to the Alberta Drug Benefit List. Effective January 1, 2016
Updates to the Alberta Drug Benefit List Effective January 1, 2016 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
More informationA PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS
A PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS BRIAN CRYDER, PHARMD BCACP LEARNING OBJECTIVES AS A RESULT OF THIS PRESENTATION, THE AUDIENCE WILL BE ABLE TO 1. DISCUSS THE KEY DIFFERENCES BETWEEN
More informationUpdate on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
More informationReversing the New Anticoagulants
Reversing the New Anticoagulants Disclosure Susan C. Lambe, MD Assistant Clinical Professor Department of Emergency Medicine University of California, San Francisco Roadmap for today 1 Roadmap for today
More informationAnticoagulation Management Insanity: doing the same thing over and over again and expecting different results. Case 1
2011 MFMER slide-1 Anticoagulation Management Insanity: doing the same thing over and over again and expecting different results Fadi Elias Shamoun, MD Mayo Clinic in Arizona Albert Einstein Anticoagulation
More informationLAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options
LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow
More informationGuideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis )
Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis ) The contents of this CPG are to be used as a guide. Healthcare professionals
More informationAHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation
AHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation A Statement for Healthcare Professionals from the American Heart Association/American Stroke
More informationImpact of new (direct) oral anticoagulants in patient blood management
Impact of new (direct) oral anticoagulants in patient blood management Yulia Lin, MD, FRCPC, CTBS Transfusion Medicine & Hematology, Sunnybrook Health Sciences Centre Dept of Laboratory Medicine & Pathobiology,
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationLaboratory Testing in Patients on Novel Oral Anticoagulants (NOACs)
Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs) Dr. Art Szkotak artur.szkotak@albertahealthservices.ca University of Alberta Hospital Edmonton, AB NOACs Direct Thrombin Inhibitors (DTI):
More informationOral Anticoagulants: What s New?
Oral Anticoagulants: What s New? Sallie Young, Pharm.D., BCPS (AQ-Cardiology) Clinical Pharmacy Specialist, Cardiology Penn State Hershey Medical Center syoung1@hmc.psu.edu August 2012 Oral Anticoagulant
More informationAnticoagulation and Reversal
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
More informationRivaroxaban (Xarelto ) by
Essentia Health Med Moment Short Video Tune-Up A brief overview of a new medication, or important new medication information Rivaroxaban (Xarelto ) by Richard Mullvain RPH BCPS (AQC) Current - August 2011
More informationThe 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
More informationWhat You Should NOAC About the New Anticoagulants. Dr Calum Young Cardiologist
What You Should NOAC About the New Anticoagulants Dr Calum Young Cardiologist Overview The Burden of AF What s Wrong With Warfarin? The Era of NOACs NOACs in New Zealand Clinical Trials with NOACs Potential
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012
More information